Shanghai MicuRx Pharmaceutical Co (688373) Fair Value & Analysis
Healthcare · CN · Market cap 3.0B CNY
Fair value as of: Jun 24, 2026
Analysis
Shanghai MicuRx Pharmaceutical Co (688373) currently trades at ¥4.47, while our model-based Fair Value estimate is ¥1.41 — implying the stock looks roughly 68.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. The company was founded in 2007 and is based in Shanghai, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Shanghai MicuRx Pharmaceutical Co (688373) undervalued?
What is the fair value of 688373?
What is the quality score of 688373?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.